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In fibrosis fibroblasts are activated and overproduce
collagen in a process with unknown drivers and equally
unknown brakes that recently implicated a novel and
surprising player, the B cell. B cells may be crucially
involved in fibrosis in several ways: B cells may produce
autoantibodies that can directly stimulate fibroblasts;
B cells can produce profibrotic cytokines such as IL-6 or
transforming growth factor beta; and, finally, B cells could
directly stimulate fibroblasts by a contact-dependent
mechanism. Recent experimental evidence suggests that
B cells can enhance collagen production by fibroblasts,
by a contact-dependent mechanism, and therefore are
profibrotic ex vivo. These data strengthen the rationale of
pursuing B-cell targeting therapies in systemic sclerosis.induction of fibroblast collagen production was lost,In fibrosis fibroblasts are activated and overproduce
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In the previous issue of Arthritis Research and Therapy,
Francois and colleagues provided experimental evidence
of a contact-dependent crosstalk between B cells and
fibroblasts; scleroderma fibroblasts exhibit a more than
twofold increase in collagen production when co-cultured
with B cells compared with when cultured alone [1]. This
B-cell-induced collagen production is comparable with
the effects of transforming growth factor beta (TGFβ), the
most potent profibrotic mediator. Enhancement of col-
lagen production was seen when fibroblasts were co-
cultured with circulating B cells only but not with whole
peripheral blood mononuclear cells. Genes encoding
collagen I and collagen III were significantly upregulated
in the B-cell/fibroblast co-culture system compared with* Correspondence: jimdaoussis@hotmail.com
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© 2013 BioMed Central Ltd.fibroblasts cultured alone. Importantly, the α-smooth
muscle actin α-SMA gene that has a key role in the differ-
entiation of fibroblasts into myofibroblasts was also
overexpressed.
When the survival factor B-cell activating factor
(BAFF) was added along with B-cell receptor-initiated
B-cell stimulation in the B-cell/fibroblast co-culture
system, a further significant enhancement of collagen
production and α-SMA expression was seen; interest-
ingly, the fibroblasts did not express any BAFF receptors.
To address the question of whether B cells interact with
fibroblasts via direct cell contact or via soluble factors,
the authors employed in some experiments a transwell
culture system allowing for a free and bidirectional dif-
fusion of soluble factors but prohibiting direct B-cell–
fibroblast contact. In these transwell experiments the
clearly indicating a contact-dependent mechanism. How-
ever, transwells only partially inhibited the effect of
BAFF + B-cell receptor stimulation on fibroblasts, indi-
cating that soluble factors also participate in the BAFF
scenario. The production of IL-6, chemokine (C–C
motif ) ligand-2 and TGFβ was significantly increased in
co-cultures and the use of transwells decreased but did
not abolish their production. Finally, blocking TGFβ
(but not blocking IL-6) led to a significant inhibition of
the effect of B cells plus BAFF on fibroblasts, suggesting
a key role for TGFβ.
There are certain issues the reader must take into
account to fully interpret this study. The authors initially
employed co-cultures of normal B cells with either
normal or systemic sclerosis (SSc) skin fibroblasts. Inter-
estingly, the results on collagen production were similar
irrespective of the fibroblasts in the co-culture. The
authors chose to continue their experiments with fibro-
blasts obtained from patients with scleroderma skin
only, again employing normal B cells in the co-culture












Figure 1 Involvement of B cells in fibrosis. B cells may be crucially involved in fibrosis in several ways: B cells may produce autoantibodies
(autoAb) that can directly stimulate fibroblasts; B cells can produce profibrotic cytokines such as IL-6 or transforming growth factor beta (TGFβ);
and, finally, B cells could directly stimulate fibroblasts by a contact-dependent mechanism. PDGFR, platelet-derived growth factor receptor.
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that the effect of normal B cells on the fibroblasts was
so strong that the activated scleroderma B cell might not
be able to produce any stronger effects. This is clearly
speculative; an experiment not performed leads to mis-
sing potentially valuable data. Therefore, the results of
the study by Francois and colleagues could apply directly
to the pathogenesis of scleroderma only if we knew that
the scleroderma B cell is a perfectly normal B cell. There
are, however, experimental data pointing to the contrary.
B cells from tight skin mice, an animal model of SSc,
exhibit enhanced CD19 signaling and are hyperres-
ponsive. Induced CD19 deficiency in tight skin mice
normalizes B-cell responses and attenuates skin fibrosis,
while B-cell depletion therapy in such models is effective
[2,3]. B cells in patients with SSc are present in the skin
[4] and the lungs [5]; expression of CD19 is increased
and the cells’ homeostasis is disturbed [6]. Microarrays
from scleroderma skin disclosed fibroblast, endothelial
cell and, surprisingly, B-cell genes to be upregulated
compared with normal skin [7]. Finally, emerging clinical
data suggest a favorable effect of the B-cell depleting
agent rituximab on skin and lung fibrosis in patients
with SSc [8-10].
How can B cells regulate the fibrotic process? B cells
may produce autoantibodies that can either directly
stimulate fibroblasts to increase collagen production
such as agonistic anti-platelet-derived growth factor
receptor autoantibodies [11], or inhibit the function of
metalloproteinases and therefore decrease collagen
degradation [12]. B cells also produce profibrotic cyto-
kines such as IL-6 or TGFβ. Finally, B cells could
directly stimulate fibroblasts via cell–cell contact.Previous experiments have shown that both B cells in
particular and, to a lesser extent, T cells can bind to
cultured fibroblasts in vitro with an as yet unknown
functional significance [13]. These are diagrammatically
depicted in Figure 1.
This study introduces the novel concept that B cells
are profibrotic ex vivo. Several questions remain to be
answered. The first question is how B cells physically
interact with fibroblasts; this should be explored in
future studies. Nevertheless, the most important issue is
whether B cells are profibrotic in vivo. The encouraging
results of several studies assessing the effect of B-cell
depletion in SSc may lead to the hypothesis that B cells
are also profibrotic in SSc. The study of Francois and
colleagues provides strong experimental evidence in
favor of a crucial role of B cells in the pathophysiology
of fibrosis and therefore strengthens the rationale of
pursuing B-cell targeting therapies in SSc.
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